Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES FIDELIO CAPITAL IN CONNECTION WITH NORDIC CAPITAL’S INVEStMENT IN ANICURA
Mandate

VINGE ADVISES FIDELIO CAPITAL IN CONNECTION WITH NORDIC CAPITAL’S INVEStMENT IN ANICURA

July 01, 2014

Vinge advises Fidelio Capital in connection with Nordic Capital’s investment in AniCura. AniCura is owned by a large number of staff, the Foundation Djursjukhus i Stor-Stockholm and the Swedish investment firm Fidelio Capital. All parties will remain significant co-owners together with Nordic Capital. Through Nordic Capital’s co-ownership, resources will be made available for, among other things, establishing a new veterinary specialist neurological centre at AniCura Albano Animal Hospital in Danderyd, Sweden. Nordic Capital’s investment is subject to approval from the relevant competition authorities.

Partners Jonas Bergström and Johan Winnerblad together with, among others, associates Peter Sundgren, Gustav Jönsson, Amanda Winberg, Johan Mattson, Emelie Klefbeck and project assistant Pernilla Warg advises Fidelio Capital. Partner Marcus Glader advises on competition law.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025